@honestderm's GLP-1 mortality claims need more context

What did @honestderm actually say?

Dr. Jamie Wiesman summarized a November 2025 retrospective study from the Journal of the American Academy of Dermatology comparing roughly 12,000 HS patients on GLP-1 agonists against 12,000 who were not. The core claim: GLP-1 users had lower overall mortality, fewer ER visits, less pain medication use, and reduced need for incision and drainage, even though they were sicker on paper. She also pushed for expanded prescribing criteria, arguing that a BMI over 27 with HS should be enough to justify a GLP-1, without requiring proven diabetes or insulin resistance.

She named semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) specifically. She also floated the idea of microdosing GLP-1 agonists in HS patients with normal BMI who still show signs of insulin resistance, and said she plans to meet with Eli Lilly to discuss clinical trials. That last part is speculative, not a finding.

Does the science back this up?

The mortality finding is striking and directionally plausible, but retrospective data can only go so far. The study design cannot rule out confounding, even with large numbers. That said, this is not a fringe claim: it fits a growing body of evidence.

GLP-1 receptor agonists have established cardiovascular and metabolic benefits in high-risk populations. The LEADER trial (Marso et al., 2016, NEJM) showed liraglutide reduced cardiovascular mortality in type 2 diabetes. The SELECT trial (Lincoff et al., 2023, NEJM) extended this to people with obesity but without diabetes. HS carries a well-documented burden of cardiometabolic comorbidity. A 2019 study by Garg et al. in the Journal of the American Academy of Dermatology confirmed significantly elevated rates of obesity, metabolic syndrome, and cardiovascular disease in HS patients. So a mortality benefit in this population, mediated through cardiometabolic improvement, is biologically coherent. The 25% reduction in ER visits and reduced surgical intervention also align with prior smaller case series suggesting GLP-1s reduce HS flares, possibly through anti-inflammatory and weight-related mechanisms.

What did they get wrong (or right)?

The missteps are mostly in the framing, not the science. The drug names were garbled throughout the transcript. Semaglutide was called "Some Agotide" and tirzepatide became "enters appetite" and "appetite." These are transcription artifacts, but they matter if patients are searching for this information.

More substantively, the microdosing suggestion deserves scrutiny. Dr. Wiesman raises a genuinely interesting hypothesis about insulin resistance in normal-weight HS patients, and there is preliminary data supporting hyperinsulinemia in HS (Acharya et al., 2023, Dermatology). But jumping from that observation to recommending "very low doses" of GLP-1 agonists outside any established protocol is speculative. No dose should be assumed safe or effective based on one retrospective study and a hypothesis. That framing should not be treated as clinical guidance.

What she got right: being transparent that this is a retrospective study and stating clearly it is not as strong as a prospective trial. That kind of methodological honesty is not common in patient-facing health content.

What should you actually know?

If you have HS and are curious about GLP-1 agonists, this study is worth knowing about, but it is not a green light to self-prescribe or assume these medications treat HS directly. The mortality reduction observed may reflect better management of cardiometabolic conditions that often accompany HS, not a direct effect on skin disease. Those are different things with different implications.

Current FDA approvals for semaglutide and tirzepatide cover type 2 diabetes and chronic weight management, not HS. Insurers generally will not cover these drugs for HS alone, and they are expensive without coverage. Dr. Wiesman's argument for expanding prescribing criteria to BMI over 27 with HS is a policy and advocacy position, not current standard of care. It may be the right position, but it is not yet reflected in guidelines.

• Talk to a physician who understands both your metabolic health and your HS severity before making any treatment changes.
• The study's racial equity finding, roughly equal distribution across groups, is worth noting. If confirmed in future research, it would address a real concern about access disparities.
• Clinical trials are the right next step. If this area interests you, watch for registered trials on ClinicalTrials.gov rather than waiting for pharmaceutical interest to materialize.

Bottom line

This is a real study with a real signal. The mortality finding in a well-powered retrospective cohort, where the GLP-1 group was actually sicker at baseline, is the kind of result that earns follow-up trials. Dr. Wiesman presented it fairly, acknowledged its limitations, and avoided overclaiming the mechanism. The microdosing idea and the prescribing expansion argument are reasonable hypotheses that need prospective data before they become recommendations. Give credit where it is due, but do not mistake a signal for a solution.